Cite
Kaparou M, Rudzki Z, Giles H, et al. Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations. Case Rep Hematol. 2021;2021:8843063doi: 10.1155/2021/8843063.
Kaparou, M., Rudzki, Z., Giles, H., Murthy, V., Srinath, S., Lloyd, R., Ahmed, M. Z., Salhan, B., Chauhan, S., Kishore, B., Lovell, R., Horgan, C., Paneesha, S., Xenou, E., Lokare, A., Ewing, J., Dassanayake, H., Nikolousis, E., & Kanellopoulos, A. (2021). Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations. Case reports in hematology, 20218843063. https://doi.org/10.1155/2021/8843063
Kaparou, Maria, et al. "Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations." Case reports in hematology vol. 2021 (2021): 8843063. doi: https://doi.org/10.1155/2021/8843063
Kaparou M, Rudzki Z, Giles H, Murthy V, Srinath S, Lloyd R, Ahmed MZ, Salhan B, Chauhan S, Kishore B, Lovell R, Horgan C, Paneesha S, Xenou E, Lokare A, Ewing J, Dassanayake H, Nikolousis E, Kanellopoulos A. Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations. Case Rep Hematol. 2021 Jan 21;2021:8843063. doi: 10.1155/2021/8843063. eCollection 2021. PMID: 33510919; PMCID: PMC7825359.
Copy
Download .nbib